Tpg Gp A, LLC Trevi Therapeutics, Inc. Transaction History

Tpg Gp A, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.54 - $4.28 $6.27 Million - $17.4 Million	-4,073,103 Reduced 94.18%	251,780 $388,000
Q2 2022 Aug 15, 2022	SELL	$1.8 - $3.39 $900,000 - $1.7 Million	-500,000 Reduced 10.36%	4,324,883 $12.2 Million
Q4 2021 Feb 14, 2022	BUY	$0.68 - $1.5 $3.28 Million - $7.24 Million	4,824,883 New	4,824,883 $3.77 Million

57.1M

136K

5.4K

Ticker TRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,322,500
Market Cap $247M
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...

Get notified when there are updates to the investment portfolio of Tpg Gp A, LLC, based on Form 13F filings with the SEC.

Stay updated on Tpg Gp A, LLC with notifications on news.